Table 3 Hazard ratio associated with ACR ≥3.5¹ for ESKD, dialysis, CVD and mortality

		Model 1^b			Model 2 ^c			Model 3 ^d
Outcome	Events	HR	95 % CI	P-value	HR	95 % CI	P-value	HR	95 % CI	P-value
Clinical Diagnosis
ESKD	12	10.7	(2.31-49.1)	0.002	9.55	(2.08-43.9)	0.004	7.60	(1.42-40.6)	0.018
Dialysis	10	17.4	(2.16-139)	0.007	15.2	(1.89-121)	0.010	13.0	(1.41-119)	0.024
CVD	31	1.79	(1.08-2.97)	0.024	1.66	(1.00-2.75)	0.052	1.23	(0.71-2.13)	0.462
Mortality
All chronic disease attributed deaths combined^e	9	2.00	(0.72-5.52)	0.182	1.99	(0.71-5.53)	0.189	2.39	(0.76-7.49)	0.136
Non-traumatic^f	17	1.59	(0.77-3.29)	0.215	1.53	(0.73-3.19)	0.262	1.94	(0.85-4.42)	0.117
All-cause mortality	18	1.12	(0.58-2.15)	0.739	1.11	(0.57-2.16)	0.751	1.40	(0.68-2.90)	0.365

^aACR < 3.5 mg/mmol as reference category and excludes 31 participants without an ACR measurement at baseline recruitment; ^bModel 1 adjusted for gender and age at baseline recruitment; ^cModel 2 adjusted for gender, age at baseline recruitment and community; ^dModel 3 adjusted for gender, age at baseline recruitment, community, and further adjusted for baseline blood pressure medication and fasting glucose at baseline; ^eAny underlying cause of death attributed to a chronic disease, including CVD, renal disease, cancer or diabetes; ^fAll deaths excluding a traumatic cause of death (such as a motor vehicle accidents). ESKD End stage kidney disease, CVD Cardiovascular disease, ACR Albumin creatinine ratio

ISSN: 1471-2369